Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03945305 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of Remote Ischemic Conditioning Treatment for Community-based Essential Hypertension

StatusRecruiting
PhaseNot applicable
SponsorYi Yang
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 28, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 31, 2024 to Jul 31, 2026v10 Show 4 more changesShow less
    • Study completion date: Apr 28, 2024 to Jul 31, 2026
    • Start date: Nov 1, 2023 to Nov 25, 2023
    • Secondary endpoints revised (4)
    • Eligibility criteria shortened, about 4 words
  2. Trial status: Not Yet Recruiting to Recruitingv9 Show 4 more changesShow less
    • Primary completion date: Jan 31, 2024 to Mar 31, 2024
    • Study completion date: Feb 28, 2024 to Apr 28, 2024
    • Start date changed from estimate of Nov 5, 2023 to Nov 1, 2023
    • Site details revised
  3. Re-verified, no change to tracked fieldsv8
  4. Enrollment target: 1000 to 500v7 Show 10 more changesShow less
    • Primary completion date: Jul 31, 2025 to Jan 31, 2024
    • Start date: Jan 3, 2023 to Nov 5, 2023
    • Primary endpoint revised
    • Study completion date: Jul 31, 2025 to Feb 28, 2024
    • Interventions: Remote Ischemic Conditioning (Device) to Patients are treated with previous antihypertensive treatment plus remote ischemic conditioning. (Device), Previous antihypertensive…
    • Eligibility criteria shortened, about 27 words
    • Secondary endpoints: 3 to 4
    • Study description shortened, about 32 words
    • Study arms: 1 to 2
    • Study title shortened, about 1 word
  5. Re-verified, no change to tracked fieldsv6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary and study completion dates: Jul 31, 2023 to Jul 31, 2025
    • Start date: Jan 3, 2022 to Jan 3, 2023
    v5
  2. Primary completion date: Dec 31, 2021 to Jul 31, 2023
    • Start date: Jan 1, 2021 to Jan 3, 2022
    • Study completion date: Jul 31, 2022 to Jul 31, 2023
    v4
  3. Primary completion date: May 31, 2020 to Dec 31, 2021
    • Start date: Jun 1, 2019 to Jan 1, 2021
    • Study completion date: Dec 31, 2020 to Jul 31, 2022
    v3
  4. Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 3 of 3 entries
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Yi Yang
17 trials monitored
See all monitored trials
Hypertension
1,925 trials monitored
See 99 trials at risk
The purpose of this study is to explore the efficacy and safety of remote ischemic conditioning for essential hypertension in the community population.
Trial Details
NCT Number NCT03945305
Lead Sponsor Yi Yang
Conditions
(from sponsor)		 Essential Hypertension
Related terms Essential Hypertension
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov